Tel Aviv University Team Uses CRISPR Technique to Destroy Metastatic Cancer Cells in Mice
source: pixabay.com

Tel Aviv University Team Uses CRISPR Technique to Destroy Metastatic Cancer Cells in Mice

     The latest news from Israeli scientists, published in the Times of Israel, is that researchers at Tel Aviv University have accurately targeted cancerous cells in mice using CRISPR.…

Continue Reading Tel Aviv University Team Uses CRISPR Technique to Destroy Metastatic Cancer Cells in Mice
Trodelvy Gets Orphan Drug Designation as a Glioblastoma Treatment
source: pixabay.com

Trodelvy Gets Orphan Drug Designation as a Glioblastoma Treatment

According to a story from GlobeNewswire, the biopharmaceutical company Immunomedics, Inc., has recently announced that its medication sacituzumab govitecan-hziy (marketed as Trodelvy) has recently earned Orphan Drug designation from the…

Continue Reading Trodelvy Gets Orphan Drug Designation as a Glioblastoma Treatment
Experimental Glioblastoma Treatment Earns Orphan Drug Designation
source: pixabay.com

Experimental Glioblastoma Treatment Earns Orphan Drug Designation

According to a story from BioSpace, the drug company Plus Therapeutics has recently announced that its investigational therapy Rhenium NanoLiposomes (RNL™) has earned Orphan Drug designation from the US Food…

Continue Reading Experimental Glioblastoma Treatment Earns Orphan Drug Designation
Even in Death, This Glioblastoma Patient’s Selfless Lego Donation Drive Touches Thousands of Lives
source: pixabay.com

Even in Death, This Glioblastoma Patient’s Selfless Lego Donation Drive Touches Thousands of Lives

According to a story from 10tv.com, Kellan Shatto is an eight year old boy who really likes to play with Legos. He also has a rare disease: neurofibromatosis. The disease…

Continue Reading Even in Death, This Glioblastoma Patient’s Selfless Lego Donation Drive Touches Thousands of Lives
Zotiraciclib, a New Treatment for Glioma, is Granted Orphan Drug Designation
Source: Pixabay.com

Zotiraciclib, a New Treatment for Glioma, is Granted Orphan Drug Designation

  The European Organization for Research and Treatment of Cancer (EORTC) has been evaluating zotiraciclib, which is a new treatment for glioma. This drug has recently been granted the Orphan…

Continue Reading Zotiraciclib, a New Treatment for Glioma, is Granted Orphan Drug Designation
Recent Study Confirms Validity of the Therapeutic Target of an Experimental Brain Cancer Drug
sbtlneet / Pixabay

Recent Study Confirms Validity of the Therapeutic Target of an Experimental Brain Cancer Drug

According to a story from BioSpace, Oncotelic, Inc., recently announced the publication of a study in the Journal of Clinical Research in Pediatrics. This study appears to back up the therapeutic…

Continue Reading Recent Study Confirms Validity of the Therapeutic Target of an Experimental Brain Cancer Drug
ICYMI: Unique Trial Design for Glioblastoma Could Lead to Numerous New Therapies
source: pixabay.com

ICYMI: Unique Trial Design for Glioblastoma Could Lead to Numerous New Therapies

Glioblastoma  Glioblastoma is a rare type of brain cancer. Sadly, it is the most aggressive form. The median life expectancy for the disease is between 11 and 15 months and…

Continue Reading ICYMI: Unique Trial Design for Glioblastoma Could Lead to Numerous New Therapies

Glioblastoma Clinical Trial: The Henry Ford Cancer Institute Enrolls the World’s First Glioblastoma Patient

  According to a recent article in CheckOrphan, glioblastoma (GBM) is considered to be among the deadliest cancers in the world. Currently, treatment options are surgery, chemotherapy, and radiation. In most cases,…

Continue Reading Glioblastoma Clinical Trial: The Henry Ford Cancer Institute Enrolls the World’s First Glioblastoma Patient
A Treatment for Newly Diagnosed Glioblastoma to be Covered Under Medicare
DarkoStojanovic / Pixabay

A Treatment for Newly Diagnosed Glioblastoma to be Covered Under Medicare

According to a story from BioPortfolio, the company Novocure has recently announced that Medicare has released final local coverage determinations for its product Optune. Optune is used to treat patients…

Continue Reading A Treatment for Newly Diagnosed Glioblastoma to be Covered Under Medicare

AI Platform Can Genetically Analyze Glioblastoma Tumors in Seconds

According to a story from seas.harvard.edu, Harvard freshman Kavya Kopparapu was reading a story about the late Senator John McCain's diagnosis with glioblastoma, a deadly brain cancer. She was stunned…

Continue Reading AI Platform Can Genetically Analyze Glioblastoma Tumors in Seconds
Glioblastoma “Vaccine” Yields Hopeful Results at End of Phase 1b Trial
source: pixabay.com

Glioblastoma “Vaccine” Yields Hopeful Results at End of Phase 1b Trial

According to a publication from EurekAlert, results from a phase 1b clinical study of experimental glioblastoma “vaccine“ IGV-001 suggest that the treatment is well tolerated in humans. Additional data collected…

Continue Reading Glioblastoma “Vaccine” Yields Hopeful Results at End of Phase 1b Trial
Korean Research Team Pioneers Method That Could Personalize Treatment for Glioblastoma
HeungSoon / Pixabay

Korean Research Team Pioneers Method That Could Personalize Treatment for Glioblastoma

According to a story from Korean Biomedical Review, a team of researchers from Seoul National University, headed by professor Paek Sun-ha, have developed an approach utilizing 3D cell printing technology…

Continue Reading Korean Research Team Pioneers Method That Could Personalize Treatment for Glioblastoma

GAPVAC Project Tests An Individualized Form of  Immunotherapy to Treat Aggressive Brain Cancer

A recent article in the journal Nature reports that Phase 1 GAPVAC-101 First-In-Human trial is one of the first clinical trials with a goal of designing and manufacturing actively personalized vaccines…

Continue Reading GAPVAC Project Tests An Individualized Form of  Immunotherapy to Treat Aggressive Brain Cancer

Oregon Health & Science University to Participate in Study to Predict Treatment Response for Rare Cancer

According to a story from IT Business Net, the medical company KIYATEC, Inc., has recently announced that that the Knight Cancer Institute at Oregon Health & Science University has joined…

Continue Reading Oregon Health & Science University to Participate in Study to Predict Treatment Response for Rare Cancer
The National Brain Tumor Society Awards $750,000 Towards Adaptive Clinical Trial for Glioblastoma
johnhain / Pixabay

The National Brain Tumor Society Awards $750,000 Towards Adaptive Clinical Trial for Glioblastoma

According to a story from pm360online.com, The National Brain Tumor Society (NBTS) recently awarded $750,000 to the Global Coalition for Adaptive Research. This cash is slated to go towards the…

Continue Reading The National Brain Tumor Society Awards $750,000 Towards Adaptive Clinical Trial for Glioblastoma

Industry First: For-Profit Donates Rights of Potential New Pediatric Leukemia Drug to Non-Profit

Notable Labs Notable Labs was created after founder, Matt De Silva, felt he was left in a helpless point, following a year of research on treatment options for his father's Glioblastoma…

Continue Reading Industry First: For-Profit Donates Rights of Potential New Pediatric Leukemia Drug to Non-Profit
Close Menu